<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT02212925</url>
  </required_header>
  <id_info>
    <org_study_id>1233.2</org_study_id>
    <nct_id>NCT02212925</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes</brief_title>
  <official_title>Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Multiple Rising Oral Doses (0.5, 2.5, 10 and 20 mg q.d. for 10 Days) of BI 14332 CL as Tablet in Female and Male Patients With Type 2 Diabetes (Randomised, Double-blind, Placebo-controlled Within the Dose Groups), Followed by a 4-week Treatment Part* (Randomised, Double-blind, Placebo-controlled) of Two Doses (Planned 5 and 20 mg) Selected on the Basis of Tolerability and DPP-4 Inhibition in the Multiple Rising Dose Part</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <brief_summary>
    <textblock>
      To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 14332&#xD;
      CL following administration of multiple rising oral doses over 10 days in patients with type&#xD;
      2 diabetes.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Terminated</overall_status>
  <start_date>November 2006</start_date>
  <primary_completion_date type="Actual">March 2007</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of patients with adverse events</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in vital signs (blood pressure, pulse rate)</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in ECG</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of patients with clinically significant findings in laboratory tests</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Assessment of tolerability by investigator on a 4-point scale</measure>
    <time_frame>up to 14 days after last drug administration</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Cmax (maximum concentration of the analyte in plasma)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>tmax (time from dosing to maximum concentration)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point within the first dosing interval)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUCτ,1 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after administration of the first dose)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ae0-24 (amount of analyte that is eliminated in urine from the time interval 0 h to 24 h)</measure>
    <time_frame>up to 11 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>fe0-24 (fraction of analyte excreted in urine from time point 0 h to 24 h)</measure>
    <time_frame>up to 11 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CLR,0-24 (renal clearance of the analyte in plasma from the time point 0 h until the time point 24 h)</measure>
    <time_frame>up to 11 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>PTF (peak trough fluctuation)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
    <description>in percent</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,Cmax (accumulation ratio based on Cmax)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>RA,AUC(accumulation ratio based on AUCτ)</measure>
    <time_frame>up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in dipeptidyl-peptidase 4 (DPP-IV) activity</measure>
    <time_frame>baseline, up to 18 days after first drug administration</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the curve of plasma glucose</measure>
    <time_frame>baseline, up to 3 hours after intake of standardized meal</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>BI 14332 CL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 14332 CL</intervention_name>
    <arm_group_label>BI 14332 CL</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male and postmenopausal or hysterectomised female patients with proven diagnosis of&#xD;
             type 2 diabetes mellitus treated with diet and exercise only, or with one oral&#xD;
             hypoglycaemic agent besides glitazones and who are not taking the maximum approved&#xD;
             dose&#xD;
&#xD;
          -  Glycosylated haemoglobin A1 (HbA1c) ≥ 6.5% and ≤ 8.5 % at screening for patients&#xD;
             treated with diet and exercise and/or one oral hypoglycaemic agent&#xD;
&#xD;
          -  Age ≥21 and Age ≤70 years (female hysterectomised and male patients) Age ≥60 and Age&#xD;
             ≤70 years (female postmenopausal patients)&#xD;
&#xD;
          -  Body Mass Index (BMI) ≥18.5 and BMI ≤35 kg/m2&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Any finding of the medical examination (including BP, pulse rate (PR) and ECG)&#xD;
             deviating from normal and of not acceptable clinical relevance&#xD;
&#xD;
          -  Clinically relevant concomitant diseases like renal insufficiency, cardiac&#xD;
             insufficiency New York Heart Association (NYHA) II-IV, myocardial infarction, other&#xD;
             known cardiovascular diseases including hypertension &gt; 140/90 mmHg, stroke and&#xD;
             transient ischemic attack&#xD;
&#xD;
          -  Gastrointestinal, hepatic, renal, respiratory, cardiovascular, metabolic,&#xD;
             immunological or hormonal disorders besides type 2 diabetes, hyperlipidaemia and&#xD;
             medically treated hypertension&#xD;
&#xD;
          -  Diseases of the central nervous system (such as epilepsy) or psychiatric disorders or&#xD;
             relevant neurological disorders besides polyneuropathy&#xD;
&#xD;
          -  Chronic or relevant acute infections (e.g. HIV, Hepatitis)&#xD;
&#xD;
          -  History of relevant allergy/hypersensitivity (including allergy to drug or its&#xD;
             excipients)&#xD;
&#xD;
          -  Intake of drugs with a long half-life (&gt; 24 hours) within at least one month or less&#xD;
             than 10 half-lives of the respective drug prior to administration or during the trial&#xD;
             except allowed co-medication&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial based on the&#xD;
             knowledge at the time of protocol preparation within 10 days prior to administration&#xD;
             or during the trial&#xD;
&#xD;
          -  Antidiabetic treatment with more than one oral hypoglycaemic agent or insulin or&#xD;
             glitazones and anti-hypertensive treatment with verapamil or diltiazem&#xD;
&#xD;
          -  Participation in another trial with an investigational drug within two months prior to&#xD;
             administration or during the trial&#xD;
&#xD;
          -  Smoker (&gt; 10 cigarettes or &gt; 3 cigars or &gt; 3 pipes/day)&#xD;
&#xD;
          -  Inability to refrain from smoking on trial days&#xD;
&#xD;
          -  Alcohol abuse (more than 40 g/day = 5 units/day)&#xD;
&#xD;
          -  Drug abuse&#xD;
&#xD;
          -  Blood donation (more than 100 mL within four weeks prior to administration or during&#xD;
             the trial)&#xD;
&#xD;
          -  Excessive physical activities (within one week prior to administration or during the&#xD;
             trial)&#xD;
&#xD;
          -  Use of drugs which might reasonably influence the results of the trial or that prolong&#xD;
             the QT/QTc interval based on the knowledge at the time of protocol preparation within&#xD;
             10 days prior to administration or during the trial&#xD;
&#xD;
          -  Any laboratory value outside the reference range and the clinical relevance is not&#xD;
             acceptable (or the value is more than three times higher than the upper limit of the&#xD;
             normal range e.g. liver enzymes)&#xD;
&#xD;
          -  Change of drug dosing of allowed co-medication (anti-hypertensive agents, acetylic&#xD;
             salicylic acid and statins) within the last 3 months&#xD;
&#xD;
          -  Fasted blood glucose &gt; 240 mg/dl (&gt;13.3 mmol/L) on two consecutive days during washout&#xD;
&#xD;
          -  Serum creatinine above upper limit of normal at screening&#xD;
&#xD;
          -  Male patients not willing to use adequate contraception (condom use plus another form&#xD;
             of contraception e.g. spermicide, oral contraceptive taken by female partner,&#xD;
             sterilisation, intrauterine device) during the whole study period from the time of the&#xD;
             first intake of study drug until one month after the last intake&#xD;
&#xD;
          -  A marked baseline prolongation of QT/QTc interval (e.g., repeated demonstration of a&#xD;
             QTc interval &gt;450 ms)&#xD;
&#xD;
          -  A history of additional risk factors for Torsade des Pointes (e.g., heart failure,&#xD;
             hypokalemia, family history of Long QT Syndrome)&#xD;
&#xD;
        For female patients:&#xD;
&#xD;
          -  Child bearing potential&#xD;
&#xD;
          -  Positive pregnancy test&#xD;
&#xD;
          -  Lactation period&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <link>
    <url>http://trials.boehringer-ingelheim.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>August 2014</verification_date>
  <study_first_submitted>August 7, 2014</study_first_submitted>
  <study_first_submitted_qc>August 7, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 8, 2014</study_first_posted>
  <last_update_submitted>August 7, 2014</last_update_submitted>
  <last_update_submitted_qc>August 7, 2014</last_update_submitted_qc>
  <last_update_posted type="Estimate">August 8, 2014</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus</mesh_term>
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT02212925
org study id: 1233.2
nct id: NCT02212925
lead sponsor: 
To investigate the safety, tolerability, pharmacokinetics, and pharmacodynamics of BI 14332
      CL following administration of multiple rising oral doses over 10 days in patients with type
      2 diabetes.
allocation: Randomized
intervention model: Parallel Assignment
primary purpose: Treatment
masking: Double
measure: Number of patients with adverse events
time frame: up to 14 days after last drug administration
measure: Number of patients with clinically significant findings in vital signs (blood pressure, pulse rate)
time frame: up to 14 days after last drug administration
measure: Number of patients with clinically significant findings in ECG
time frame: up to 14 days after last drug administration
measure: Number of patients with clinically significant findings in laboratory tests
time frame: up to 14 days after last drug administration
measure: Assessment of tolerability by investigator on a 4-point scale
time frame: up to 14 days after last drug administration
measure: Cmax (maximum concentration of the analyte in plasma)
time frame: up to 18 days after first drug administration
measure: tmax (time from dosing to maximum concentration)
time frame: up to 18 days after first drug administration
measure: AUC0-tz (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to the last quantifiable data point within the first dosing interval)
time frame: up to 18 days after first drug administration
measure: AUCτ,1 (area under the concentration-time curve of the analyte in plasma over the time interval from 0 to 24 h after administration of the first dose)
time frame: up to 18 days after first drug administration
measure: Ae0-24 (amount of analyte that is eliminated in urine from the time interval 0 h to 24 h)
time frame: up to 11 days after first drug administration
measure: fe0-24 (fraction of analyte excreted in urine from time point 0 h to 24 h)
time frame: up to 11 days after first drug administration
measure: CLR,0-24 (renal clearance of the analyte in plasma from the time point 0 h until the time point 24 h)
time frame: up to 11 days after first drug administration
measure: Cmin,ss (minimum measured concentration of the analyte in plasma at steady state over a uniform dosing interval)
time frame: up to 18 days after first drug administration
measure: Cpre,N (predose concentration of the analyte in plasma at steady state immediately before administration of the next dose N)
time frame: up to 18 days after first drug administration
measure: PTF (peak trough fluctuation)
time frame: up to 18 days after first drug administration
description: in percent
measure: RA,Cmax (accumulation ratio based on Cmax)
time frame: up to 18 days after first drug administration
measure: RA,AUC(accumulation ratio based on AUCτ)
time frame: up to 18 days after first drug administration
measure: Change in dipeptidyl-peptidase 4 (DPP-IV) activity
time frame: baseline, up to 18 days after first drug administration
measure: Area under the curve of plasma glucose
time frame: baseline, up to 3 hours after intake of standardized meal
arm group label: BI 14332 CL
arm group type: Experimental
arm group label: Placebo
arm group type: Placebo Comparator
intervention type: Drug
intervention name: BI 14332 CL
arm group label: BI 14332 CL
intervention type: Drug
intervention name: Placebo
arm group label: Placebo
criteria: 
gender: All
minimum age: 21 Years
maximum age: 70 Years
healthy volunteers: No
url: http://trials.boehringer-ingelheim.com
description: Related Info
responsible party type: Sponsor
mesh term: Diabetes Mellitus
mesh term: Diabetes Mellitus, Type 2